

Research

Open Access

Surfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model

Paola E Cogo*^{†1}, Gianna Maria Toffolo^{†2}, Carlo Ori^{†3}, Andrea Vianello^{†4}, Marco Chierici^{†2}, Antonina Gucciardi^{†1}, Claudio Cobelli^{†2}, Aldo Baritussio^{†5} and Virgilio P Carnielli^{†6,7}

Address: ¹Department of Pediatrics, University of Padova, Padova, Italy, ²Department of Information Engineering, University of Padova, Padova, Italy, ³Department of Pharmacology, Anaesthesia and Critical Care, University of Padova, Padova, Italy, ⁴Respiratory Unit, General Medical Hospital, Padova, Italy, ⁵Department of Medical and Surgical Sciences, University of Padova, Padova, Italy, ⁶Neonatal Division, Salesi Children's Hospital, Ancona, Italy and ⁷Nutrition Unit, Institute of Child Health and Great Ormond Street Hospital, London, UK

Email: Paola E Cogo* - cogo@pediatria.unipd.it; Gianna Maria Toffolo - toffolo@dei.unipd.it; Carlo Ori - carloori@unipd.it; Andrea Vianello - andrea.vianello@sanita.padova.it; Marco Chierici - marco.chierici@dei.unipd.it; Antonina Gucciardi - spec2@child.pedi.unipd.it; Claudio Cobelli - cobelli@dei.unipd.it; Aldo Baritussio - aldo.baritussio@unipd.it; Virgilio P Carnielli - v.carnielli@ich.ucl.ac.uk

* Corresponding author †Equal contributors

Published: 21 February 2007

Received: 28 August 2006

Respiratory Research 2007, **8**:13 doi:10.1186/1465-9921-8-13

Accepted: 21 February 2007

This article is available from: <http://respiratory-research.com/content/8/1/13>

© 2007 Cogo et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: In patients with acute respiratory distress syndrome (ARDS), it is well known that only part of the lungs is aerated and surfactant function is impaired, but the extent of lung damage and changes in surfactant turnover remain unclear. The objective of the study was to evaluate surfactant disaturated-phosphatidylcholine turnover in patients with ARDS using stable isotopes.

Methods: We studied 12 patients with ARDS and 7 subjects with normal lungs. After the tracheal instillation of a trace dose of ¹³C-dipalmitoyl-phosphatidylcholine, we measured the ¹³C enrichment over time of palmitate residues of disaturated-phosphatidylcholine isolated from tracheal aspirates. Data were interpreted using a model with two compartments, alveoli and lung tissue, and kinetic parameters were derived assuming that, in controls, alveolar macrophages may degrade between 5 and 50% of disaturated-phosphatidylcholine, the rest being lost from tissue. In ARDS we assumed that 5–100% of disaturated-phosphatidylcholine is degraded in the alveolar space, due to release of hydrolytic enzymes. Some of the kinetic parameters were uniquely determined, while others were identified as lower and upper bounds.

Results: In ARDS, the alveolar pool of disaturated-phosphatidylcholine was significantly lower than in controls (0.16 ± 0.04 vs. 1.31 ± 0.40 mg/kg, $p < 0.05$). Fluxes between tissue and alveoli and *de novo* synthesis of disaturated-phosphatidylcholine were also significantly lower, while mean resident time in lung tissue was significantly higher in ARDS than in controls. Recycling was 16.2 ± 3.5 in ARDS and 31.9 ± 7.3 in controls ($p = 0.08$).

Conclusion: In ARDS the alveolar pool of surfactant is reduced and disaturated-phosphatidylcholine turnover is altered.

Background

ARDS is a syndrome of reduced gas exchange due to a diffuse injury to the alveolar capillary barrier and is characterized by filling of the alveoli with proteinaceous fluid, infiltration by inflammatory cells and consolidation [1]. It may develop after a direct insult to the lung parenchyma or it may result from inflammatory processes carried into the lungs via the pulmonary vasculature. In the early exudative phase of ARDS the massive, self-perpetuating inflammatory process is characterized by an increased endothelial and epithelial permeability with leakage of plasma components.

Constriction and microembolism of the pulmonary vessels are also present, leading to ventilation perfusion mismatch. Moreover an increase in the alveolar surface tension causes alveolar instability, atelectasis and ventilatory inhomogeneities. In severe ARDS, just a small fraction of parenchyma remains aerated, and the damage can be so widespread that normal parenchyma, as judged by computed tomography, may shrink to 200–500 g [2,3].

One of the hallmarks of ARDS is reduced lung compliance and loss of stability of terminal airways at low volumes, suggesting surfactant dysfunction or deficiency. Samples of bronchoalveolar lavage fluid from patients with ARDS have low concentrations of disaturated-phosphatidylcholine, phosphatidylglycerol and surfactant-specific proteins and fail to reduce surface tension both *in vitro* and *in vivo* [4,5]. Surfactant organization in the alveoli is also altered, since large aggregates, the active fraction of surfactant, decrease in patients with ARDS [6]. To our knowledge, the alveolar pool of surfactant has never been rigorously estimated in patients with ARDS, nor is it known if surfactant turnover is altered in this condition.

Data on surfactant metabolism in ARDS are available from animal studies which showed a faster turnover rate and a decreased alveolar pool of disaturated-phosphatidylcholine, while the tissue pool was increased in some studies and unchanged in others [7-9]. However these experiments cannot be repeated in humans and may not necessarily mimic human disease.

In this paper we studied the turnover of surfactant disaturated-phosphatidylcholine in patients with ARDS and in control subjects. To this end we instilled a trace dose of ^{13}C -dipalmitoyl-phosphatidylcholine into the trachea and then followed over time the ^{13}C enrichments in disaturated-phosphatidylcholine-palmitate isolated from serial tracheal aspirates.

Available evidence indicates that surfactant dipalmitoyl-phosphatidylcholine is recycled several times before being degraded by alveolar macrophages or within lung paren-

chyma [7]. There is uncertainty, however, about the contribution of alveolar macrophages to surfactant catabolism, since animal experiments indicate that alveolar macrophages could degrade between 5 and 50% of surfactant disaturated-phosphatidylcholine [10,11]. In patients with ARDS, the fraction of disaturated-phosphatidylcholine degraded in the alveolar space could be even greater than this, due to the presence of inflammatory cells, bacteria and free hydrolytic enzymes [12,13]. On the basis of these considerations we assumed that alveolar macrophages may degrade 5–50% of saturated phosphatidylcholine in controls and 5–100% in patients with ARDS.

Methods

Patients

We studied 12 adult patients with ARDS, defined according to Bernard [14], and 7 subjects with normal lungs on mechanical ventilation or breathing spontaneously through a tracheostomy tube due to neuromuscular diseases. Patients were admitted to the Intensive Care or Respiratory Units of the University of Padova, Italy. The study was approved by the Ethics Committee, and written, informed consent was obtained. After intubation with a cuffed tube, all patients received into the trachea 20 ml of normal saline containing 7.5 mg of ^{13}C -dipalmitoyl-phosphatidylcholine and 40 mg of surfactant extract (Curosurf[®], Chiesi, Parma, Italy) as spreading agent. Both palmitates were uniformly labeled with carbon 13 ([U- ^{13}C -PA]-DPPC, Martek-Biosciences, Columbia, MD). The suspension was instilled close to the carina with a 4.5 mm bronchoscope (Olympus BF-40 OD 6.0 mm Olympus-Europe, Italy). Patients with ARDS were studied within 72 h from the onset of the acute respiratory failure and ventilator parameters were adjusted to maintain an oxygen saturation > 85% and pH > 7.25. Ventilator and gas exchange parameters were recorded at time 0 and subsequently every 6 h in ARDS patients and at least once in controls.

Study design

Tracheal aspirates, collected by suction below the tip of the endotracheal tube after instilling 5 ml of normal saline, were obtained at baseline, every 6 h until 72 h and then every 12 h for 7 days or until extubation. Aspirates were filtered on gauze, centrifuged at 150-g for 10 minutes and supernatants were stored at -20°C.

Analytical methods

Lipids from tracheal aspirates and from the administered tracer were extracted according to Bligh and Dyer after addition of the internal standard heptadecanoylphosphatidylcholine [15]. One third of the extract was oxidized with osmium tetroxide. Disaturated-phosphatidylcholine was isolated from the lipid extract by thin layer chromatography [16], the fatty acids were deri-




Figure 1

A two compartment model. Two compartment model for the analysis of disaturated-phosphatidylcholine-palmitate kinetics. Compartment 1 is the alveolar space, compartment 2 is lung tissue. M_1 and M_2 are tracee disaturated-phosphatidylcholine-palmitate masses, P is disaturated-phosphatidylcholine-palmitate *de novo* synthesis, F_{21} and F_{12} are inter-conversion fluxes, F_{01} and F_{02} are irreversible loss fluxes, k_{21} and k_{12} are interconversion rate parameters, k_{01} and k_{02} are irreversible loss rate parameters, u is the tracer disaturated-phosphatidylcholine-palmitate input in compartment 1 and the dashed line with a bullet indicates the tracer to tracee ratio (ttr) measurement. It is assumed that loss from the alveolar space is 5–50% in controls and 5–100% in ARDS.

vatized as pentafluorobenzyl derivatives [17], extracted with hexane and stored at -20°C . Tracheal aspirates with visible blood were discarded. The enrichments of ^{13}C - disaturated-phosphatidylcholine-palmitate were measured by gas chromatography-mass spectrometry (GC-MS, Voyager, Thermoquest, Rodano, Milano, Italy), as previously described [18].

Data analysis

Data were analyzed with the two compartment model shown in figure 1 under the following assumptions: a) surfactant is distributed between two compartments (alveoli and lung parenchyma); b) disaturated-phosphatidylcholine is synthesized by lung parenchyma, secreted in

the alveoli and recycled before being degraded by alveolar macrophages or lung tissue; c) the system is at steady state and is not perturbed by the administration of tracer. These assumptions have been validated in adult and newborn animals by several authors, and have been used in numerous studies on surfactant turnover in experimental animals [7,19-21].

Tracer model equations are:

$$\dot{m}_1(t) = -(k_{01} + k_{21})m_1(t) + k_{12}m_2(t) + u(t)$$

$$\dot{m}_2(t) = k_{21}m_1(t) - (k_{02} + k_{12})m_2(t) \quad (1)$$

Table 1: Clinical characteristics of patients with ARDS and control subjects

	ARDS N = 12	CONTROLS N = 7	p
Body Weight (kg)	74 ± 16	58 ± 12	0.05
Age (years)	60 ± 16	50 ± 23	0.37
Mechanical Ventilation (days)	23 ± 16	81 ± 129	0.21
Mechanical Ventilation at the start of the study (days)	2.6 ± 2	69 ± 132	0.23
Male/Female (number)	8/4	3/4	0.324
Survival (alive/total number)	4/12	7/7	0.006
Mean FiO ₂ (percentage)	60 ± 16	24 ± 14	<0.001
Mean PEEP (cm H ₂ O)	7.7 ± 1.8	1.3 ± 0.2	<0.001
Mean AaDO ₂ §	283 ± 129	52 ± 38	<0.001
Mean PaO ₂ /FiO ₂ *	162 ± 50	382 ± 79	<0.001

§ AaDO₂ = Mean Alveolar-arterial oxygen gradient during the study

* PaO₂/FiO₂ = PaO₂/FiO₂ ratio during the study period

Data is presented as mean ± SD

where m_1 and m_2 are the amount (in mg) of disaturated-phosphatidylcholine-palmitate tracer in compartment 1 and 2 respectively, \dot{m}_1 and \dot{m}_2 (mg/h) represent their rate of change, k_{21} and k_{12} (h⁻¹) are inter-conversion rate parameters, k_{01} and k_{02} (h⁻¹) are irreversible losses, and u is the labeled disaturated-phosphatidylcholine-palmitate injection into the accessible compartment.

Tracee steady state equations are:

$$0 = -(K_{01} + K_{21})M_1 + K_{12}M_2 = -F_{01} - F_{21} + F_{12}$$

$$0 = K_{21}M_1 - (K_{01} + K_{12})M_2 + P = F_{21} - F_{01} - F_{12} + P \quad (2)$$

where M_1 and M_2 (mg) are the steady state tracee disaturated-phosphatidylcholine-palmitate masses in the two compartments, P (mg/h) is disaturated-phosphatidylcholine-palmitate *de novo* synthesis, $F_{21} = k_{21}M_1$, $F_{12} = k_{12}M_2$, $F_{01} = k_{01}M_1$, $F_{02} = k_{02}M_2$ (mg/h) are inter-conversion and irreversible loss fluxes.

Measured tracer to tracee ratio at time t is the ratio between tracer and tracee masses in the accessible compartment:

$$\text{trr}_1(t) = \frac{m_1(t)}{M_1} \quad (3)$$

The tracer model (equations 1 and 3) is not identifiable, since it is not possible to quantify from the input-output tracer experiment in the alveolar compartment unique values for the unknown parameters of the tracer model, namely M_1 , k_{01} , k_{02} , k_{12} , k_{21} [22]. Only the mass in the alveolar compartment M_1 can be uniquely identified, together with some combinations of the original parameters, namely $k_{01} + k_{21}$, $k_{02} + k_{21}$ and $k_{21}k_{12}$. To resolve model nonidentifiability, assumptions on the relative role

of the two degradation pathways need to be incorporated into the model. Based on the results of studies in which rabbits or mice received non-degradable analogues of disaturated-phosphatidylcholine into the trachea [10,11], we assumed that, in normal subjects, alveolar macrophages may degrade between 5 and 50% of surfactant disaturated-phosphatidylcholine, the remaining being degraded by lung parenchyma (i.e. F_{01} varies between 5 and 50% of $F_{01} + F_{02}$). In ARDS, we assumed that the degradation of disaturated-phosphatidylcholine in the airways could vary between 5 and 100% due to the degradative activity of inflammatory cells, bacteria or enzymes released in the alveolar spaces (i.e. F_{01} varies between 5 and 100% of $F_{01} + F_{02}$). Using this information, upper and lower bounds for parameters k_{12} , k_{21} , k_{01} and k_{02} were estimated from tracer to tracee data in each individual [23]. Using these values in equation 2, upper and lower bounds were derived for P , M_2 and tracee fluxes F_{21} and F_{02} , while flux F_{12} was uniquely solved [22]. Additional kinetic parameters were used to characterize the system, namely the total mass in the system ($M_{\text{tot}} = M_1 + M_2$), the mean residence time of molecules entering the system from alveoli or lung tissue (MRT_1 , MRT_2), defined as the sum of the elements in column 1 and 2 of the mean residence time matrix Θ :

$$\Theta = \begin{bmatrix} -(k_{01} + k_{21}) & k_{12} \\ k_{21} & -(k_{02} + k_{12}) \end{bmatrix}^{-1} = \frac{1}{k_{21}k_{02} + k_{01}k_{02} + k_{01}k_{12}} \begin{bmatrix} k_{02} + k_{12} & k_{12} \\ k_{21} & k_{01} + k_{21} \end{bmatrix} \quad (4)$$

and the percentage R (%) of particles that recycle back after leaving the intracellular pool:

$$R = \frac{k_{21}}{k_{21} + k_{01}} \cdot \frac{k_{12}}{k_{12} + k_{02}} \quad (5)$$

Upper and lower bound were calculated for M_{tot} , MRT_1 and MRT_2 [22], while unique values were calculated for R .

Table 2: Clinical characteristics of patients with ARDS

Patient	Sex	Weight (kg)	Age (years)	Intubation [‡] (days)	Survival (Y/N)	Main Diagnosis	PaO ₂ /FiO ₂ M/m* (%)	AaDO ₂ M/mx [§] (mmHg)
Pt1	F	48	86	24/5	N	Gastric ulcer, MOSF [†]	221/171	140/159
Pt2	M	95	27	11/1	N	Polytrauma, MOSF [†]	136/82	423/575
Pt3	F	57	47	6/0	N	Rectal cancer, MOSF [†]	145/111	235/279
Pt4	M	88	69	33/3	N	Sepsis post pancreatectomy	132/70	382/482
Pt5	M	90	53	49/6	Y	Politrauma, lung contusions	153/63	399/608
Pt6	M	69	59	6/3	N	Gastrectomy, MOSF [†]	82/62	555/590
Pt7	M	88	62	15/1	Y	Sepsis	194/58	177/605
Pt8	F	52	46	47/3	Y	Cirrhosis, liver transplant	146/92	276/396
Pt9	M	78	71	42/5	Y	Candida Pneumonia	268/187	158/260
Pt10	M	70	61	11/4	N	Gastric Cancer	156/87	214/414
Pt11	F	60	69	18/0	N	Pancreatic Cancer	118/70	267/333
Pt12	M	88	74	13/5	N	Pancreatitis	195/129	173/227

[‡] Intubation = number of days of intubation/days of intubation at the start of the study

[†] MOSF = Multi Organ System Failure

* PaO₂/FiO₂ M/m = PaO₂/FiO₂ ratio Mean/minimum during the study period

[§]AaDO₂M/mx = Alveolar-arterial oxygen gradient Mean/maximum during the study period

Model identifiability

Parameters k_{21} , k_{12} , k_{01} , k_{02} , and M_1 of the model (figure 1) were fitted on disaturated-phosphatidylcholine-palmitate tracer to tracee ratio using SAAMII [24]. Weights were chosen optimally, i.e. equal to the inverse of the measurement errors. They were assumed to be Gaussian, independent and zero mean with a constant coefficient of variation, which was estimated a posteriori.

Masses of palmitate residues were multiplied by 1.3025 to obtain disaturated-phosphatidylcholine masses. Rate of changes (k), fluxes (F) and synthesis (P) were multiplied by 24 to obtain the respective values per day.

Statistical analysis

Results are presented as mean \pm SEM. Data in Table 1 are presented as mean \pm SD. Differences were analysed using the Mann-Whitney test with a 2-tailed probability of <0.05 (SPSS 10.0, Windows 2000). Parameters, resolved as upper and lower bounds, were considered different when the interval of admissible values in ARDS was significantly different from the interval of admissible values in controls.

Results

Clinical characteristics

We studied 12 ARDS patients and 7 controls. No ARDS patient was treated with exogenous surfactant. Eight ARDS patients (67%) died before hospital discharge, 5 for multi-organ failure and 3 for the underlying disease. Patients died within 4 to 18 days of study completion and during the study respiratory and gas exchange parameters were stable. No death occurred in the control group. In the control group, five patients suffered from spinal muscular atrophy, two had polyneuropathy and one had encephalopathy secondary to head injury. Clinical characteristics of the 12 ARDS and 7 controls are reported in

Table 1. ARDS was induced by an indirect insult in all but one patient (patient 5, Table 2). Mean age was comparable in the two groups, mean weight was significantly lower in control groups ($p = 0.05$) and the male/female ratio was 8/4 in ARDS and 3/4 in controls ($p = 0.26$). Ventilator parameters were significantly different as expected from the study design. All ARDS patients were mechanically ventilated, whereas six controls were on intermittent ventilator support and one was breathing spontaneously via tracheostomy tube. Table 2 reports detailed clinical data for the 12 ARDS patients.

Kinetic calculations

The average time courses of disaturated-phosphatidylcholine-palmitate tracer to tracee ratio in controls and ARDS are shown in figure 2. Although similar tracer doses were used in ARDS and controls, the tracer to tracee ratio of ARDS was markedly higher than in controls. In both cases, the tracer to tracee ratio declined to negligible values at 96 h. Therefore we used data up to 96 h.

Individual curves of the tracer to tracee ratio were fitted to the model presented in figure 1. All parameters were estimated with acceptable precision, on average less than 50%. Kinetic parameters are summarized in figure 3 and depicted in greater detail in figure 4. Three of them (M_1 , F_{12} and R) were uniquely identified, the others are presented as ranges of values included between two extremes, the upper and lower bounds.

In controls, the alveolar pool of disaturated-phosphatidylcholine was 1.31 ± 0.40 mg/kg, far smaller than the tissue pool, which, depending on assumptions about degradation of disaturated-phosphatidylcholine by alveolar macrophages, ranged from 9.64 ± 2.43 to 19.35 ± 3.74 mg/kg. *De novo* synthesis (P) of disaturated-phosphatidylcholine ranged from 4.25 ± 0.7 to 8.64 ± 1.44 mg/kg/day.






Figure 2
Tracer to tracee ratio plot. Tracer to tracee ratio (ttr) in disaturated-phosphatidylcholine and palmitate isolated from tracheal aspirates in ARDS (upper) and controls (lower). Values are mean \pm SEM. n = 7 for control subjects and 12 for patients with ARDS.

**Figure 3**

Main kinetic results. Disaturated-phosphatidylcholine-palmitate kinetics in ARDS (left) and controls (right). Unique values are estimated only for M_1 and F_{12} . Other parameters are presented as ranges, limited by average upper and lower bounds.

The flux from alveoli to tissue (F_{21}) ranged from 3.12 ± 1.49 to 4.80 ± 1.78 mg/kg/day. The flux from tissue to alveoli (F_{12}) was 5.23 ± 1.78 mg/kg/day and recycling (R) was $31.9 \pm 7.3\%$. According to the model, labelled disaturated-phosphatidylcholine is expected to accumulate into the lung parenchyma of control subjects, reaching a maximum concentration between 12 and 24 hours after instillation. Afterwards, tissue isotopic enrichment is expected to decrease, so that 96 hours after the start of the study around 20% of the tracer remains associated with lung tissue (data not shown).

In patients with ARDS, the alveolar pool of disaturated-phosphatidylcholine (M_1) was smaller than in controls: 0.16 ± 0.04 vs 1.31 ± 0.40 mg/kg ($p < 0.05$). Fluxes between tissue and alveoli (F_{12} and F_{21}) and *de novo* synthesis (P) of disaturated-phosphatidylcholine were also smaller than in controls. Fractional rates of transfer between tissue and airways (k_{21} and k_{12}) and alveolar mean resident time (MRT_1) were not different from controls. In ARDS, the tissue mean resident time of disaturated-phosphatidylcholine was significantly longer than in controls (figure 3 and 4). Recycling tended to be smaller in patients with ARDS, but the difference was not significant: $16.2\% \pm 3.5$ in ARDS and $31.9\% \pm 7.3$ in controls ($p = 0.08$, figure 4). Differences between ARDS and control patients appear to be robust, since, with the excep-

tion of the synthesis rate P , all differences remained significant even assuming that in controls 5–100% of disaturated-phosphatidylcholine can be degraded in the alveolar spaces.

The model predicts that in ARDS instilled disaturated-phosphatidylcholine associates rapidly with lung tissue, reaching a maximum after 12–24 hours, and then decreases gradually, so that after 96 hours 10–30% of the dose remains tissue-associated (not shown).

Discussion

Pulmonary surfactant is essential for normal lung function, and it is well established that surfactant impairment contributes to respiratory failure in ARDS [4,5,25-27]. These observations prompted the use of exogenous surfactant in ARDS, to replenish a deficient state and reverse surfactant inactivation [28-30]. However, large randomized clinical trials have given puzzling results [28-30] suggesting that other processes, besides surfactant dysfunction, may contribute to lung damage in ARDS or at least indicating that exogenous surfactant is either rapidly inactivated or is preferentially distributed to normal lung sections.

Most of our knowledge on surfactant kinetics in acute lung injury derives from animal studies done with radio-




Figure 4
Detailed kinetic results. Estimated and derived kinetic parameters of ARDS patients (black boxes) and controls (white boxes). Values are expressed as mean ± SEM. Symbols as in figure [1]. Stars (*) represent unique values in ARDS that were significantly lower (p < 0.05) than the respective values in controls. Crosses (†) indicate intervals of admissible values in ARDS significantly lower than in controls (upper bound in ARDS significantly lower than lower bound in controls). Double crosses (‡) indicate intervals of admissible values in ARDS significantly higher than in controls (lower bound in ARDS significantly higher than upper bound in controls).

active isotopes [7]. In this study we analysed the turnover of surfactant disaturated-phosphatidylcholine in control subjects and in patients with ARDS using stable isotopes. The technique used has been validated in pre-term baboons with bronchopulmonary dysplasia. In that experiment we found that the estimate of the alveolar and tissue pools of disaturated phosphatidylcholine obtained from the dilution of stable isotopes in tracheal aspirates compared well with direct measurements done at autopsy. [31]. The technique has been also applied to human infants with neonatal respiratory distress syndrome due to prematurity, lung malformations and infections [18,32-36]. However there are aspects of the present work, both conceptual and technical, that warrant special comment.

Basic assumptions

The design of the study assumes that the tracer was administered as a pulse, that there was good mixing between tracer and endogenous surfactant, that the administered material did not perturb endogenous surfactant, that tracheal aspirates were representative of events happening in the most peripheral airways and that patients were at steady state.

While in neonatal respiratory disorders the lung parenchyma is relatively homogeneous, this is certainly not the case in patients with ARDS, where areas of atelectasis and over-distension coexist and the tracer might distribute preferentially to aerated sections of the lungs [3]. In this study, to optimize distribution, we mixed the tracer with a surfactant extract used as a spreading agent. We could not document directly in our patients that the instilled material distributed uniformly throughout the aerated airways, but we relied on the following findings all indicating that the instilled material mixed well with resident surfactant: a) animals who receive surfactant through the airways with the technique we used, display a rather homogeneous distribution through the airways, [37-39]; b) our estimate of the alveolar pool of disaturated-phosphatidylcholine in control patients agrees very nicely with data obtained by Rebello et al on bronchoalveolar lavage fluid of human cadaver lungs [40]; c) in preterm baboons we found that the disaturated-phosphatidylcholine pools calculated from the dilution of tracers administered through the trachea compare well with direct measurements done at autopsy [31]; d) in the same experiment we found the disaturated-phosphatidylcholine tracer enrichments in tracheal aspirates were remarkably similar to the enrichments measured in the bronchoalveolar lavage fluid (data not shown).

The dose of disaturated-phosphatidylcholine administered to control subjects (20 ± 2 mg) represented 1.1–2.1% of the estimated lung pool [5], an amount unlikely

to perturb endogenous surfactant. In patients with ARDS, the dose (20 ± 2 mg) represented 5.0–13.1% of the estimated lung pool, an amount also unlikely to induce a pharmacologic effect, considering that the doses of surfactant used for the treatment of ARDS are at least two orders of magnitude greater [29,30]. Since the dose of surfactant administered was small and clinical conditions remained stable during the study, we assume that the system was at steady state, thus allowing the use of a linear time invariant compartmental model to describe disaturated-phosphatidylcholine kinetics.

Data were analysed according to the two compartment model reported in figure 1. This model is physiologically plausible, but too complex to be uniquely resolvable from the available data, since only the mass in the alveolar compartment (M_1), the flux from the lung tissue back to the alveolar space (F_{12}) and recycling (R) can be uniquely solved. Only a far more complex experiment, with tracer administered also in the lung tissue compartment, could permit to uniquely identify all kinetic parameters. Since this experiment could not be done, we used existing knowledge on the contribution of alveolar macrophages to surfactant degradation to derive bounds for parameters that could not be uniquely identified. Thus, on the basis of animal experiments done by Gurel and Rider [10,11], we assumed that alveolar macrophages could normally degrade between 5 and 50% of surfactant disaturated-phosphatidylcholine, the remaining being degraded by the lung parenchyma. It should be noted however, that 50% degradation by alveolar macrophages probably represents a maximum, since this figure was derived on the assumption that alveolar macrophages do not re-enter lung parenchyma after the uptake of surfactant in the alveoli [10]. In ARDS, we assumed that 5–100% of surfactant disaturated-phosphatidylcholine could be degraded in the airways, due to the degradative activity of inflammatory cells or bacteria. By incorporating these assumptions into the tracer-tracee model, upper and lower bounds were derived for all non identifiable kinetic parameters, following a strategy formalized in [23] and applied to study thyroid hormones [41,42] and glucose [43] kinetics.

Surfactant kinetic parameters in controls

Our estimate of the alveolar and tissue pools of disaturated-phosphatidylcholine in controls agree quite well with measurements taken by Rebello et al. during autopsies of adults without lung disease [40]. In fact, according to Rebello et al. the alveolar and tissue pools contain respectively $1.9 \mu\text{mol/kg}$ and $28.4 \mu\text{mol/kg}$ of disaturated-phosphatidylcholine. We found that in controls the alveolar pool of disaturated-phosphatidylcholine was $2.3 \mu\text{mol/kg}$, while the tissue pool ranged between 17.1 and $34.3 \mu\text{mol/kg}$. It is also of note that our results compare favorably with those of Martini et al. who studied sur-

factant turnover in adult pigs using stable isotopes [44]. These authors reported that mean phosphatidylcholine synthesis was 4.7 mg/kg/day, while our estimate ranged between 4.3 and 8.6 mg/kg/day. Furthermore they reported that the phosphatidylcholine tissue pool was 10 times higher than the alveolar pool [44], in good agreement with our finding that in control subjects the tissue pool was 7.6–14.8 times greater the alveolar pool. Overall, these results support our approach and also indicate that tracheal aspirates can be as useful as bronchoalveolar lavage fluid for the study of surfactant turnover.

Using morphometric methods Young et al. estimated that the alveolar pool of disaturated-phosphatidylcholine is comparable to the lamellar body pool [45]. Thus it is likely that the tissue pool of disaturated-phosphatidylcholine measured with the present technique includes both intracellular surfactant and non-surfactant membranes that, with time, incorporate a fraction of administered disaturated-phosphatidylcholine.

Surfactant in ARDS

In patients with ARDS alveolar pool, fluxes between tissue and alveoli and *de novo* synthesis of disaturated-phosphatidylcholine were all smaller than in controls, while the mean residence time in lung tissue was greater than in controls. These differences appear to be robust, since, with the exception of *de novo* synthesis, they persist even assuming that in controls alveolar macrophages degrade between 5% and 100% of surfactant disaturated-phosphatidylcholine. Thus most of our conclusions remain valid independent of any assumption regarding the site of degradation of surfactant.

The present results agree with the view that, in ARDS, only a fraction of the lung is accessible to exogenous surfactant. In fact, the decrease of the alveolar pool of disaturated-phosphatidylcholine, the decrease of fluxes between tissue and alveoli and the decrease in the rate of synthesis can all be interpreted assuming that instilled surfactant reached only aerated lung sections. However, our data do not support the notion that these residual lung sections were normal, since the mean resident time of disaturated-phosphatidylcholine in lung parenchyma (MRT_2) was greater while the rate of recycling tended to be lower than in controls. The greater mean residence time of disaturated-phosphatidylcholine in lung tissue could be due to a number of factors, namely to a decreased ability to degrade surfactant components, to an increased reacylation of lysophosphatidylcholine (favored by the increased availability of palmitate residues generated by phospholipase A_2 , released by inflammatory cells), to a proliferation of type II cells, to the distribution of tracer to lung structures not pertaining to the surfactant system (i.e. infiltrating inflammatory cells), or to a combination of these

phenomena [46]. The distribution of tracer to lung structures not pertaining to the surfactant system could explain the tendency towards a less efficient recycling of DSPC observed in patients with ARDS (figure 4).

Conclusion

Surfactant pool size is greatly diminished in ARDS compared to control, and surfactant kinetics is altered in ARDS resulting from a significantly reduced production rate and a significantly longer retention time in the 2nd (tissue) compartment.

The fact that the alveolar pool of disaturated-phosphatidylcholine can be estimated unambiguously is an important result of this work. In future studies this approach could be used to relate changes in surfactant turnover with time course and severity of ARDS or to evaluate the effect of different treatments (ventilation modes, inhaled or intravenous therapies) on surfactant metabolism.

Abbreviations

ARDS = acute respiratory distress syndrome

k_{21} and k_{12} = disaturated-phosphatidylcholine inter-conversion rate parameters,

k_{01} and k_{02} = disaturated-phosphatidylcholine irreversible losses,

u = labeled disaturated-phosphatidylcholine-palmitate injection into the accessible compartment.

M_1 = the alveolar pool of disaturated-phosphatidylcholine

M_2 = the tissue pool of disaturated-phosphatidylcholine

M_{tot} = total disaturated-phosphatidylcholine pool

F_{21} , F_{12} , F_{01} , F_{02} = disaturated-phosphatidylcholine inter-conversion and irreversible loss fluxes in compartment 1 (alveoli) and 2 (tissue)

P = *De novo* synthesis of disaturated-phosphatidylcholine

MRT_1 and MRT_2 = mean residence time of disaturated-phosphatidylcholine in compartment 1 (alveoli) and 2 (tissue)

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

PEC participated to the design and coordination of the study and drafted the manuscript. GMT, MC, CC performed the data modeling and analysis. CO and AV were responsible of the clinical conduction of the study. AG performed the mass spectrometry analysis. BA and VPC participated in the study design and helped to draft the manuscript.

Acknowledgements

We thank all patients who took part in the study and all the nurses for their precious contribution to the collection of the tracheal samples.

This study was funded by a grant from University of Padova, Italy and partially supported by Ministero dell'Università e della Ricerca Scientifica, Italy.

References

- Ware LB, Matthay MA: **The Acute Respiratory Distress Syndrome.** *New Engl J Med* 2000, **342**:1334-1349.
- Gattinoni L, Chiumello D, Cressoni M, Valenza F: **Pulmonary computed tomography and adult respiratory distress syndrome.** *Swiss Med Wkly* 2005, **135**:169-174.
- Gattinoni L, Pesenti A: **The concept of baby lung.** *Intensive Care Med* 2005, **31**:776-784.
- Frerking I, Gunther A, Seeger W, Pison U: **Pulmonary surfactant: functions, abnormalities and therapeutic options.** *Intensive Care Med* 2001, **27**:1699-1717.
- Haitsma JJ, Papadakos PJ, Lachmann B: **Surfactant therapy for acute lung injury/acute respiratory distress syndrome.** *Curr Opin Crit Care* 2004, **10**:18-22.
- Panda AK, Nag K, Harbottle RR, Rodriguez-Capote K, Veldhuizen RA, Petersen NO, Possmayer F: **Effect of acute lung injury on structure and function of pulmonary surfactant films.** *Am J Respir Cell Mol Biol* 2004, **30**:641-650.
- Jobe AH: **Phospholipid Metabolism and Turnover.** In *Fetal and Neonatal Physiology* Edited by: Polin RA and Fox WW. Philadelphia, W. B. Saunders Company; 1992.
- Malloy J, McCaig L, Veldhuizen RA, Yao LJ, Joseph M, Whitsett J, Lewis J: **Alterations of endogenous surfactant system in septic adult rats.** *Am J Respir Crit Care Med* 1997, **156**:617-623.
- Lewis JF, Ikegami M, Jobe A: **Altered surfactant function and metabolism in rabbits with acute lung injury.** *J Appl Physiol* 1990, **69**:2303-2310.
- Gurel O, Ikegami M, Chroneos ZC, Jobe AH: **Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs.** *Am J Physiol Lung Cell Mol Physiol* 2001, **280**:L1266-72.
- Rider ED, Ikegami M, Jobe A: **Intrapulmonary catabolism of surfactant-saturated phosphatidylcholine in rabbits.** *J Appl Physiol* 1990, **69**:1856-1862.
- Atallah HL, Wu Y, Alaoui-El-Azer M, Thouron F, Koumanof K, Wolf C, Brochard L, Harf A, Delclaux C, Touqui L: **Induction of type-IIA secretory phospholipase A2 in animal model of acute lung injury.** *Eur Respir J* 2003, **21**:1040-1045.
- Fisher AB, Dodia C: **Lysosomal-type PLA2 and turnover of alveolar DPPC.** *Am J Physiol Lung Cell Mol Physiol* 2001, **280**:L748-54.
- Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall R, Morris A, Spragg R: **The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trials coordination.** *Am Rev Respir Dis* 1994, **149**:818-824.
- Bligh EG, Dyer WJ: **A rapid method of total lipid extraction and purification.** *Can J Biochem Physiol* 1959, **37**:911-917.
- Mason J, Nellenbogen J, Clements JA: **Isolation of desaturated phosphatidylcholine with osmium tetroxide.** *J Lipid Res* 1976, **17**:281-284.
- Christie WW: **The analysis of fatty acids.** In *Gas chromatography and lipids A practical guide* Edited by: Christie WW. Ayr, Scotland, The oil press; 1989:64-84.
- Torresin M, Zimmermann LJI, Cogo PE, Cavicchioli P, Badon T, Giordano G, Zacchello F, Sauer PJJ, Carnielli VP: **Exogenous Surfactant Kinetics in Infant Respiratory Distress Syndrome: a Novel Method with Stable Isotopes.** *Am J Respir Crit Care Med* 2000, **161**:1584-1589.
- Pinto RA, Wright JR, Lesikar D, Benson BJ, Clements JA: **Uptake of pulmonary surfactant protein C into adult rat lung lamellar bodies.** *J Appl Physiol* 1993, **74**:1005-1011.
- Hallman M, Epstein BL, Gluck L: **Analysis of labeling and clearance of lung surfactant phospholipids in rabbit. Evidence of bidirectional surfactant flux between the lamellar bodies and alveolar lavage.** *J Clin Invest* 1981, **68**:742-751.
- Baritussio A, Pettenazzo A, Benevento M, Alberti A, Gamba P: **Surfactant protein C is recycled from the alveoli to the lamellar bodies.** *Am J Physiol* 1992, **263**:L607-L611.
- Cobelli C, Foster D, Toffolo G: . In *Tracer Kinetics in Biomedical Research* New York, USA, Plenum Publisher; 2000.
- DiStefano JJ: **Complete parameter bounds and quasi-identifiability conditions for a class of unidentifiable linear system.** *Math Biosci* 1983, **65**:51-68.
- Barret PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster D: **SAAMII: simulation, analysis and modeling software for tracer and pharmacokinetics studies.** *Metabolism* 1998, **47**:484-492.
- Nakos G, Kitsioulis EI, Tsangaris I, Lekka ME: **Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components.** *Intensive Care Med* 1998, **24**:296-303.
- Baudouin SV: **Exogenous surfactant replacement in ARDS-one day, someday, or never?** *New Engl J Med* 2004, **351**:853-855.
- Schmidt R, Meier U, Yabut-Perez M, Walrath D, Grimminger F, Seeger W, Gunther A: **Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia.** *Am J Respir Crit Care Med* 2001, **163**:95-100.
- Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN: **Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome.** *N Engl J Med* 1996, **334**:1417-1421.
- Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ: **Bovine surfactant therapy for patients with acute respiratory distress syndrome.** *Am J Respir Crit Care Med* 1997, **155**:1309-1315.
- Spraag RG, Lewis JF, Walrath HD, Johannigman J, Bellingan G, Latere PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Hafner D, Taut FJ, Seeger W: **Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.** *New Engl J Med* 2004, **351**:884-892.
- Janssen DJ, Carnielli VP, Cogo PE, Seidner SR, Luijendijk IHI, Wattimena DJL, Jobe AH, Zimmermann LJI: **Surfactant phosphatidylcholine half-life and pool size measurements in premature baboons developing BPD.** *Pediatr Res* 2002, **52**:724-729.
- Janssen DJ, Tibboel D, Carnielli VP, van Emmen E, Luijendijk IHI, Wattimena JLD, Zimmermann LJI: **Surfactant phosphatidylcholine pool size in human neonates with congenital diaphragmatic hernia requiring ECMO.** *J Pediatr* 2003, **142**:247-252.
- Cogo PE, Carnielli VP, Bunt JEH, Badon T, Giordano G, Zacchello F, Sauer PJJ, Zimmermann LJI: **Endogenous surfactant metabolism in critically ill infants measured with stable isotopes labeled fatty acids.** *Pediatr Res* 1999, **45**:242-246.
- Cogo PE, Zimmermann LJI, Rosso F, Tormena F, Gamba P, Verlatto G, Baritussio A, Carnielli VP: **Surfactant synthesis and kinetics in infants with congenital diaphragmatic hernia.** *Am J Respir Crit Care Med* 2002, **166**:154-158.
- Cogo PE, Zimmermann LJI, Pesavento R, Sacchetto E, Burighel A, Rosso F, Badon T, Verlatto G, Carnielli VP: **Surfactant Kinetics in Preterm Infants on mechanical ventilation who did and did not develop Bronchopulmonary Dysplasia (BPD).** *Crit Care Med* 2003, **31**:1532-1538.
- Cogo PE, Zimmermann LJI, Meneghini L, Mainini N, Bordignon L, Suma V, Buffo M, Carnielli VP: **Pulmonary surfactant disaturated-phosphatidylcholine (DSPC) turnover and pool size in newborn infants with congenital diaphragmatic hernia (CDH).** *Pediatr Res* 2003, **54**:653-658.
- Oyazumy MJ, Clements JA, Baritussio A: **Ventilation enhances pulmonary alveolar clearance of radioactive dipalmitoyl phos-**

- phatidylcholine in liposomes.** *Am Rev Respir Dis* 1980, **121**:709-721.
38. Davis JM, Russ GA, Metlay L, Dickerson B, Greenspan BS: **Short term distribution kinetics of intratracheally administered exogenous lung surfactant.** *Pediatr Res* 1992, **31**:445-450.
 39. Ueda T, Ikegami M, Rider ED, Jobe A: **Distribution of surfactant and ventilation in surfactant-treated preterm lambs.** *J Appl Physiol* 1994, **76**:45-55.
 40. Rebello CM, Jobe AH, Eisele JW, Ikegami M: **Alveolar and tissue surfactant pool sizes in humans.** *Am J Respir Crit Care Med* 1996, **154**:625-628.
 41. DiStefano JJ, Malone TK, Jang M: **Comprehensive kinetics of thyroxine (T4) distribution and metabolism in blood and tissue pools of the rat from only 6 blood samples: dominance of large, slowly exchanging tissue pool.** *Endocrinology* 1982, **111**:108-117.
 42. DiStefano JJ, Jang M, Malone TK, Broutman M: **Comprehensive kinetics of triiodothyronine (T3) production distribution and metabolism in blood and tissue pools of the rat using optimised blood sampling protocol.** *Endocrinology* 1982, **110**:198-213.
 43. Cobelli C, Toffolo G: **Theoretical aspects and practical strategies for the identification of unidentifiable compartmental systems.** In *Identifiability of Parametric Models* Edited by: Walter E. Oxford, Pergamon Press; 1987:85-91.
 44. Martini WZ, Chinkes DL, Barrow RE, Murphey ED, Wolfe RR: **Lung surfactant kinetics in conscious pigs.** *Am J Physiol* 1999, **277**:E187-95.
 45. Young SL, Kremers SA, Apple JS, Crapo JD, Brumley GW: **Rat lung surfactant kinetics biochemical and morphometric correlation.** *J Appl Physiol* 1981, **51**:248-253.
 46. Fisher AB, Dodia C, Feinstein SI, Ho YS: **Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2.** *J Lipid Res* 2005, **46**(6):1248-56.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

